MiR‐150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1

The association of microRNAs (miRs) with cancer progression has been established in many cancers including esophageal squamous cell carcinoma (ESCC). A public microarray database showed that the expression of miR‐150 was lower in ESCC than in normal esophageal mucosa. Here, we focused on ZEB1, epithelial‐mesenchymal‐transition (EMT)‐inducer, as a target gene of miR‐150 based on in silico predictions. The purpose of this study was to clarify the clinicopathological significance of miR‐150 in ESCC, and to investigate miR‐150′s EMT‐regulatory ability. Quantitative RT‐PCR was used to evaluate miR‐150 expression in 108 curative resected ESCC samples to determine the clinicopathological significance. Moreover, we examined the in vitro and in vivo function of miR‐150 via degradation of ZEB1. MiR‐150 expression was significantly lower in cancer tissues compared to adjacent non‐cancerous tissues (P < 0.001). Low expression of miR‐150 in ESCC contributed to malignant potential, such as tumor depth, lymph node metastasis, lymphatic invasion, venous invasion, clinical staging, and poor prognosis (P < 0.05). In vitro assays showed that EMT‐inducer‐ZEB1 is a new direct target of miR‐150. Moreover, miR‐150 induced MET‐like changes in TE‐8 cells through ZEB1 degradation (e.g., E‐cadherin expression, vimentin repression, epithelial morphology, and suppression of migration ability), and significantly inhibited tumorigenicity and tumor growth in a mouse xenograft model. Analysis of the regulation of ZEB1 by miR‐150 could provide new insights into preventing metastasis and also suggests novel targeted therapeutic strategies in ESCC. (Cancer Sci 2013; 104: 48–54)

[1]  M. Chen,et al.  miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1 , 2012, Clinical & Experimental Metastasis.

[2]  Ha Won Kim,et al.  microRNA-150 Regulates Mobilization and Migration of Bone Marrow-Derived Mononuclear Cells by Targeting Cxcr4 , 2011, PloS one.

[3]  I. Haviv,et al.  The social aspects of EMT-MET plasticity , 2011, Nature Medicine.

[4]  S. Law,et al.  MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor , 2011, Gut.

[5]  M. Soares,et al.  Identification of Differentially Expressed MicroRNAs in Osteosarcoma , 2011, Sarcoma.

[6]  K. Basso,et al.  Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. , 2011, Blood.

[7]  Jiannis Ragoussis,et al.  Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization , 2011, Nature Medicine.

[8]  H. Tagawa,et al.  The role of microRNA-150 as a tumor suppressor in malignant lymphoma , 2011, Leukemia.

[9]  Simone Brabletz,et al.  The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? , 2010, EMBO reports.

[10]  M. Herlyn,et al.  Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. , 2010, Cancer research.

[11]  Tint Lwin,et al.  microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. , 2010, Blood.

[12]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[13]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[14]  S. Fedele,et al.  MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. , 2009, Recent patents on cardiovascular drug discovery.

[15]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[16]  Borja Saez,et al.  Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth , 2008, Molecular Cancer Research.

[17]  Robert G. Ramsay,et al.  MYB function in normal and cancer cells , 2008, Nature Reviews Cancer.

[18]  M. Korpal,et al.  The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.

[19]  T. Komori,et al.  Snail‐associated epithelial–mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression , 2008, The Journal of pathology.

[20]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[21]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[22]  D. Sugarbaker,et al.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Val Gebski,et al.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.

[24]  G. Hannon,et al.  Control of translation and mRNA degradation by miRNAs and siRNAs. , 2006, Genes & development.

[25]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[26]  R. Malthaner,et al.  Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis , 2004, BMC medicine.

[27]  鈴木 茂正 Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness , 2012 .

[28]  George A. Calin,et al.  RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.

[29]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[30]  F. Saggioro,et al.  MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. , 2009, The Journal of clinical endocrinology and metabolism.

[31]  Fang Zhou,et al.  Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. , 2008, Cancer research.

[32]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[33]  H. Soifer,et al.  MicroRNAs in disease and potential therapeutic applications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.